| INPHARMATICA and Galapagos Genomics enter Drug Discovery collaboration London, UK, and Mechelen, Belgium, April 29, 2003 – Inpharmatica Ltd a leading informatics-driven drug discovery company, and Galapagos Genomics NV, the Belgian functional genomics company, today announced that they have entered into a drug discovery collaboration. Under
the terms of the collaboration, Inpharmatica will use its unique
chemogenomics technology platform, PharmaCarta™, to determine
the druggability of targets selected by Galapagos in its internal
disease programs. Galapagos will provide Inpharmatica access to
its PhenoSelectTM adenoviral expression platform for a subset of
Inpharmatica’s novel nuclear receptors. Inpharmatica will
use the adenoviral technology in its in-house programmes to further
validate and prioritise these receptors as targets for drug development.
Financial terms of the agreement were not disclosed. “Galapagos’
unique PhenoSelect™ technology will enable us to efficiently
functionally characterize and therefore prioritise our portfolio
of novel nuclear receptors,” said Inpharmatica’s CEO,
Dr. Malcolm Weir. “This collaboration further reflects the
increasing demand for access to PharmaCarta™ and the growing
recognition of the enormous benefits of using a unified chemogenomics
platform, based on comprehensive and expert data analysis and interpretation,
and powerful informatics, to drive the gene- to- drug discovery
process.” Notes to Editors: Galapagos
Genomics NV: http://www.galapagosgenomics.com/ Inpharmatica
: www.inpharmatica.com Founded in 1998, Inpharmatica is based on research from Professor Janet Thornton’s group at University College London. Employing approximately 100 staff, Inpharmatica is headquartered in London and has its own in-house laboratory facilities. These laboratory facilities provide experimental validation of in-silico discoveries, enabling Inpharmatica (and its strategic partners) to advance novel drug targets identified through its application of PharmaCarta™ and to develop novel drugs against those targets. Inpharmatica
operates a hybrid business model with three distinct components: Internal Drug Discovery is focused upon discovering, validating and finding leads against highly druggable targets mined from the human genome, and has resulted in the company filing patents over more than 200 novel proteins to date. The company’s lead discovery program is focused upon the development of 16 novel nuclear receptors (“NR’s”). NR’s are a family of proteins widely considered to be both druggable and of high therapeutic interest. Drugs targeted against NR’s generate more than $10bn in sales annually. Inpharmatica’s novel NR’s represent a more than 30% increase on those identified in the public domain. PharmaCarta is the Company’s knowledge-based chemogenomics technology platform which drives the discovery process from gene to drug candidate. Inpharmatica applies PharmaCarta both in collaboration with third parties and for internal drug discovery. The Company concluded its first PharmaCarta collaboration, for the identification of novel protein therapeutics, with Serono in July 2001, a collaboration that was further expanded in January 2003. In February 2003 the Company concluded a further PharmaCarta collaboration with Chiron. Biopendium is the Company’s proteome annotation resource, accessed by partners through commercial license. It is the world’s most comprehensive annotation resource; enabling rapid high throughput annotation of large datasets for target prioritisation, target mining and microarray analysis. Inpharmatica’s multi-year non-exclusive subscription collaborators include Pfizer, Genentech, Serono and Daiichi. Inpharmatica also has a joint venture with Celera to develop a special edition of the Biopendium that incorporates Celera’s proprietary genomic data (Celera Edition Biopendium). Contact details: Inpharmatica Galapagos
Genomics
|
 |
| Disclaimer © Copyright 2008 Galapagos NV |